GW Pharmaceuticals has rolled out Sativex oromucosal spray in Denmark, following approval from the health authorities of Denmark.
Developed by GW Pharma, Sativex oromucosal spray is indicated as a treatment for the relief of spasticity in multiple sclerosis (MS).
The spray is already been marketed in Spain, the UK and Germany.
The company expects to launch Sativex oromucosal spray in Sweden in 2011.
Aditionally, GW Pharma anticipates the launch of Sativex in Czech Republic, Italy and Austria in 2012.
Currently, the company is evaluating Sativex in Phase III trial for the treatment of caner pain.